Is Gossamer Bio Inc. (GOSS) Good For Your Portfolio?


Gossamer Bio Inc. (NASDAQ:GOSS) saw an upside of 5.53% to close Monday at $2.10 after adding $0.11 on the day. The 5-day average trading volume is 3,798,260 shares of the company’s common stock. It has gained $2.3500 in the past week and touched a new high 1 time within the past 5 days. An average of 4,443,275 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 6,411,078.

GOSS’s 1-month performance is 0.96% or $0.2000 on its low of $1.7100 reached on 12/27/22. The company’s shares have touched a 52-week low of $1.57 and high of $15.19, with the stock’s rally to the 52-week high happening on 01/13/23. YTD, GOSS has lost -3.23% or -$0.0700 and has reached a new high 6 times. However, the current price is down -86.18% from the 52-week high price.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Insider Transactions

GOSS stock investors last saw insider trading activity on Oct 24.Peterson Caryn (EVP, Regulatory Affairs) most recently sold 4,757 shares at $12.07 per share on Oct 24. This transaction cost the insider $57,431. Chief Scientific Officer, Carter Laura, sold 4,876 shares at a price of $12.07 on Oct 24. Then, on Oct 24, Chief Medical Officer Aranda Richard sold 4,757 shares at a price of $12.07 per share. This transaction amounted to $57,431.

Valuation Metrics

GOSS stock has a beta of 1.10. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 3.39.

Gossamer Bio Inc.’s quick ratio for the period ended June 29 was 5.90, with the current ratio over the same period at 5.90. As well, the company’s long term debt to equity for the quarter ending June 29 was 3.73, while the total debt to equity was 3.93. The firm’s gross profit as reported stood at $19.44 million against revenue of $216.12 million.

Earnings Surprise

For the quarterly period ending June 29 this year, Gossamer Bio Inc.’s cash and short-term investments amounted to $150.91 million against total debt of $220.73 million. Net income and sales went up compared to those figures reported in the previous quarter. Net income shrunk -1.5% to -$59.36 million, while revenue of -$56.47 million was 4.87% off the previous quarter. Analysts expected GOSS to announce -$0.7 per share in earnings in its latest quarter, but it posted -$0.74, representing a -5.70% surprise. EBITDA for the quarter stood at more than -$55.02 million. GOSS stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 267.19 million, with total debt at $220.73 million. Shareholders hold equity totaling $94.48 million.

Let’s look briefly at Gossamer Bio Inc. (GOSS) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 23 January was 42.16% to suggest the stock is trending Neutral, with historical volatility in this time period at 101.46%.

The stock’s 5-day moving average is $2.0200, reflecting a -10.26% or -$0.2400 change from its current price. GOSS is currently trading +7.69% above its 20-day SMA, -84.59% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -79.31% and SMA200 by-76.00%.

Stochastic %K and %D was 22.29% and 24.08% and the average true range (ATR) pointed at 0.2600. The RSI (14) points at 35.74%, while the 14-day stochastic is at 36.23% with the period’s ATR at 0.3400. The stock’s 9-day MACD Oscillator is pointing at -0.1800 and -0.1700 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for Gossamer Bio Inc. (NASDAQ: GOSS), SMBC Nikko downgraded it to a Neutral rating. They previously had an Outperform rating on the stock. Analysts offering their rating for GOSS stock have a consensus rating for the stock as Overweight. Currently, 1 brokerage advisors rate GOSS as a “sell,”, while 2 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 1 rates the stock as overweight while 9 have offered a “buy” rating.

What is GOSS’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $2.00 and a high of $15.00, with their median price target at $7.00. Looking at these predictions, the average price target given by analysts is for Gossamer Bio Inc. (GOSS) stock is $7.42.


Please enter your comment!
Please enter your name here